Spinale Muskelatrophie (SMA)
Reference35 articles.
1. Baranello G, Darras BT, Day JW et al. Risdiplam in Type 1 Spinal Muscular Atrophy. The New England journal of medicine. 2021; 384(10): 915–923. DOI: 10.1056/NEJMoa2009965.
2. Bertini E, Burghes A, Bushby K et al. 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11–13 February 2005, Naarden, The Netherlands. Neuromuscular Disorders. 2005; 15(11): 802–816. DOI: 10.1016/j.nmd.2005.07.005.
3. Biogen. Fachinformation Spinraza. 2021.
4. Calucho M, Bernal S, Alías L et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscular disorders, NMD. 2018; 28(3): 208–215. DOI: 10.1016/j.nmd.2018.01.003.
5. Castro D, Finkel RS, Farrar MA et al. Nusinersen in Infantile-onset Spinal Muscular Atrophy: Results from Longer-term Treatment from the Open-label SHINE Extension Study (1640). Neurology. 2020; 94 (15 Supplement): 1640.